Regeneron antibody therapy available to COVID-19 patients with certain risk factors

KPRC

UTMB’s Dr. Shawn Nishi was on KPRC Ch. 2 to talk about the importance of monoclonal antibody treatment for people who have “mild to moderate disease, COVID positive, they’re not in the hospital yet. Those without symptoms who qualify are those patients that are high risk for disease progression.”